Biomarker & Intervention Discovery
Peripheral Artery Disease (PAD)
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
Spontaneous remissionProgressive disease; spontaneous improvement rare; limb ischaemia worsens in 25-30% over 5 years; major adverse limb…
Best-intervention remissionSupervised exercise therapy (SET): equivalent to endovascular revascularisation for claudication at 6-12 months…
Gap sizeVery large — supervised exercise therapy is first-line in guidelines but almost no patient is referred; PAD remains…
Primary barrieraccess/framing
Full remission profile →
Remission & chronicity
Spontaneous remission
Progressive disease; spontaneous improvement rare; limb ischaemia worsens in 25-30% over 5 years; major adverse limb events (MALE) in 10-15%/year in advanced PAD; major amputation in 5-10% at 5 years without revascularisation
Best-intervention remission
Supervised exercise therapy (SET): equivalent to endovascular revascularisation for claudication at 6-12 months (CLEVER trial); revascularisation: 70-80% 1-year limb salvage; SGLT2 inhibitors + GLP-1 agonists reduce MALE by 15-20% (AMPLITUDE-O, EMPA-REG); rivaroxaban + aspirin (COMPASS trial): 46% reduction in MALE
Gap size
Very large — supervised exercise therapy is first-line in guidelines but almost no patient is referred; PAD remains vastly underdiagnosed
Primary barrier
access/framing
PAD is underdiagnosed (ABI testing rarely performed in primary care); supervised exercise therapy is guideline Class IA recommendation but reimbursed and accessible for <5% of PAD patients; cilostazol (PDE3 inhibitor) improves walking but is contraindicated in heart failure (common comorbidity); PAD mortality often exceeds coronary disease mortality in this population
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Peripheral Artery Disease (PAD)” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."